TY - JOUR
T1 - Complications of HIPEC for ovarian cancer surgery
T2 - evaluation over two time periods
AU - Navarro Santana, Beatriz
AU - Garcia-Torralba, Esmeralda
AU - Viveros-Carreño, David
AU - Rodriguez, Juliana
AU - Pareja, Rene
AU - Martin, Alicia
AU - Forte, Sara
AU - Krause, Kate J.
AU - González-Martín, J. M.
AU - Ramirez, Pedro T.
N1 - © IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/9/5
Y1 - 2023/9/5
N2 - Objective Cytoreductive surgery in conjunction with hyperthermic intraperitoneal chemotherapy (HIPEC) is being explored in the upfront, interval, and recurrent setting in patients with ovarian cancer. The objective of this systematic review was to assess the rate of complications associated with HIPEC in epithelial ovarian cancer surgery over two time periods. Methods This study was registered in PROSPERO (CRD42022328928). A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Ovid/Medline, Ovid/Embase, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials were searched from January 2004 to April 2022. We included studies reporting on patients with advanced primary or recurrent epithelial ovarian cancer who underwent cytoreductive surgery and HIPEC. We evaluated two different time periods: 2004-2013 and 2014-2022. A random-effects meta-analysis was used to produce an overall summary. Subgroup analyses were planned according to recruited period for each specific complication type. Heterogeneity was assessed using the I 2 statistic. Results A total of 4928 patients were included from 69 studies for this systematic review; 19 published from 2004-2013, and 50 published from 2014-2022. No significant differences were found between the two time periods in terms of blood transfusions (33% vs 51%; p=0.46; I 2 =95%) overall gastrointestinal complications (15% vs 21%; p=0.36; I 2 =98%), infectious diseases (16% vs 13%; p=0.62; I 2 =93%), overall respiratory complications (12% vs 12%; p=0.88; I 2 =91%), overall urinary complications (6% vs 12%; p=0.06; I 2 =94%), or thromboembolic events (5% vs 3%; p=0.25; I 2 =63%). Also, no differences were found in intensive care unit (ICU) admissions (89% vs 28%; p=0.06; I 2 =99%), reoperations (8% vs 7%; p=0.50; I 2 =37%), or deaths (3% vs 3%; p=0.77; I 2 =57%). Conclusions Our review showed that overall complications have not changed over time for patients undergoing HIPEC in the setting of primary or recurrent ovarian cancer. There was no decrease in the rates of ICU admissions, reoperations, or deaths.
AB - Objective Cytoreductive surgery in conjunction with hyperthermic intraperitoneal chemotherapy (HIPEC) is being explored in the upfront, interval, and recurrent setting in patients with ovarian cancer. The objective of this systematic review was to assess the rate of complications associated with HIPEC in epithelial ovarian cancer surgery over two time periods. Methods This study was registered in PROSPERO (CRD42022328928). A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Ovid/Medline, Ovid/Embase, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials were searched from January 2004 to April 2022. We included studies reporting on patients with advanced primary or recurrent epithelial ovarian cancer who underwent cytoreductive surgery and HIPEC. We evaluated two different time periods: 2004-2013 and 2014-2022. A random-effects meta-analysis was used to produce an overall summary. Subgroup analyses were planned according to recruited period for each specific complication type. Heterogeneity was assessed using the I 2 statistic. Results A total of 4928 patients were included from 69 studies for this systematic review; 19 published from 2004-2013, and 50 published from 2014-2022. No significant differences were found between the two time periods in terms of blood transfusions (33% vs 51%; p=0.46; I 2 =95%) overall gastrointestinal complications (15% vs 21%; p=0.36; I 2 =98%), infectious diseases (16% vs 13%; p=0.62; I 2 =93%), overall respiratory complications (12% vs 12%; p=0.88; I 2 =91%), overall urinary complications (6% vs 12%; p=0.06; I 2 =94%), or thromboembolic events (5% vs 3%; p=0.25; I 2 =63%). Also, no differences were found in intensive care unit (ICU) admissions (89% vs 28%; p=0.06; I 2 =99%), reoperations (8% vs 7%; p=0.50; I 2 =37%), or deaths (3% vs 3%; p=0.77; I 2 =57%). Conclusions Our review showed that overall complications have not changed over time for patients undergoing HIPEC in the setting of primary or recurrent ovarian cancer. There was no decrease in the rates of ICU admissions, reoperations, or deaths.
KW - ovarian neoplasms
KW - postoperative complications
UR - http://www.scopus.com/inward/record.url?scp=85171757918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85171757918&partnerID=8YFLogxK
U2 - 10.1136/ijgc-2023-004658
DO - 10.1136/ijgc-2023-004658
M3 - Article
C2 - 37669829
AN - SCOPUS:85171757918
SN - 1048-891X
VL - 34
SP - 1
EP - 9
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 1
ER -